title: [Thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha].
authors.forename: J
authors.initials: J
authors.lastname: Montero-Tinnirello
authors.forename: J
authors.initials: J
authors.lastname: de la Fuente-Aguado
authors.forename: M S
authors.initials: MS
authors.lastname: Rodríguez-Pecci
authors.forename: F J
authors.initials: FJ
authors.lastname: Fernández-Fernández
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000139:chemically induced*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b